Licensing status

Publication and contact information

Disease models

Mouse model of early T cell precursor acute lymphoblastic leukemia (ETP-ALL) with IL-7 receptor (CD127) mutation

A mouse model of ETP-ALL could help identify new therapeutics for the disease. In immature thymocytes, expression of a mutant form of CD127 found in pediatric cases of ETP-ALL blocked differentiation of thymocytes early in development. In irradiated mice, transplantation of thymocytes expressing mutant Cd127, but not wild-type Cd127, caused lethal leukemia with similar gene expression patterns as the human pediatric cancers. In the ETP-ALL mouse model, the Janus kinase-1 (JAK-1) and JAK-2 inhibitor Jakafi ruxolitinib increased survival compared with vehicle. Next steps could include using the model to identify other therapeutics for ETP-ALL.
Incyte Corp. and Novartis AG market Jakafi to treat myeloproliferative disorder.

SciBX 7(18); doi:10.1038/scibx.2014.539
Published online May 8, 2014

Patent and licensing status unavailable

Treanor, L.M. et al. J. Exp. Med.; published online March 31, 2014;
Contact: Brian P. Sorrentino, St. Jude Children's Research Hospital, Memphis, Tenn.